Literature DB >> 25476188

[Guidelines on "pharmacotherapy of neurodegenerative dementia": an update].

K Fassbender1, L Frölich.   

Abstract

This article presents the evidence-based pharmacotherapeutic options for the most common forms of neurodegenerative dementia. The aim is to present the recommendations derived from the relevant studies on the neurological, psychiatric and geriatric practice of treatment for dementia patients. The text is derived from the 2009 guidelines of the German Society of Neurology (DGN, lead management: K. Fassbinder), the S3 guidelines of the DGN/German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN, lead management: G. Deuschl and W. Maier) and the latest amendments of the European Federation of Neurological Societies/European Society of Neurology (EFNS-ENS, Sorbi et al. Eur J Neurol 19:1159-1179, 2012) guidelines. The forms of neurodegenerative dementia addressed are Alzheimer's disease, frontotemporal dementia and Lewy body dementia. Specific statements on the treatment of dementia in Parkinson's disease and vascular dementia can be found in separate guidelines. An analogous article on psychosocial interventions was recently published in Der Nervenarzt (Kurz, Nervenarzt 84:93-103, 2013).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25476188     DOI: 10.1007/s00115-014-4189-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  44 in total

Review 1.  [Pharmacological treatment options in frontotemporal dementia].

Authors:  H Kessler; T Supprian; P Falkai
Journal:  Fortschr Neurol Psychiatr       Date:  2006-09-14       Impact factor: 0.752

2.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

Review 3.  [Dementia in advanced age: estimating incidence and health care costs].

Authors:  H Bickel
Journal:  Z Gerontol Geriatr       Date:  2001-04       Impact factor: 1.281

4.  Incidence of dementia according to DSM-III-R and ICD-10: results of the Leipzig Longitudinal Study of the Aged (LEILA75+), Part 2.

Authors:  S G Riedel-Heller; A Busse; C Aurich; H Matschinger; M C Angermeyer
Journal:  Br J Psychiatry       Date:  2001-09       Impact factor: 9.319

5.  Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.

Authors:  Edgar R Miller; Roberto Pastor-Barriuso; Darshan Dalal; Rudolph A Riemersma; Lawrence J Appel; Eliseo Guallar
Journal:  Ann Intern Med       Date:  2004-11-10       Impact factor: 25.391

Review 6.  Donepezil for dementia due to Alzheimer's disease.

Authors:  J S Birks; R Harvey
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 7.  Switching cholinesterase inhibitors in patients with Alzheimer's disease.

Authors:  M Emre
Journal:  Int J Clin Pract Suppl       Date:  2002-06

8.  Frontotemporal dementia: a randomised, controlled trial with trazodone.

Authors:  Florence Lebert; Willy Stekke; Christine Hasenbroekx; Florence Pasquier
Journal:  Dement Geriatr Cogn Disord       Date:  2004       Impact factor: 2.959

9.  Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study.

Authors:  A Ott; M M Breteler; F van Harskamp; J J Claus; T J van der Cammen; D E Grobbee; A Hofman
Journal:  BMJ       Date:  1995-04-15

Review 10.  Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Authors:  Michal Rolinski; Chris Fox; Ian Maidment; Rupert McShane
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.